CJC-1295 and CJC-1295+DAC are often grouped together in search results, but they represent two meaningfully different research tools built from the same GHRH analogue core. One is the 29 residue modified GRF fragment used to probe GHRH receptor signalling with short, controllable exposure windows. The other adds a Drug Affinity Complex via a modified lysine, shifting how the molecule behaves in circulation based study models and changing how researchers plan timing, sampling, and interpretation.
Science Research Studies- CJC-1295 vs CJC-1295+DAC Peptides
CJC-1295 and CJC-1295+DAC
are frequently searched together because both are built from a modified GRF one to twenty nine core used in growth hormone releasing hormone receptor studies. The important distinction is not the target class, but the design intent: CJC-1295 is typically treated as the compact signalling scaffold, while CJC-1295+DAC adds a Drug Affinity Complex extension that is discussed as a way to prolong apparent exposure in model systems through albumin association. That single architectural change can reshape how researchers plan sampling windows, compare acute versus extended receptor drive, and interpret kinetic patterns across assays. This comparison defines each molecule clearly, describes the structural difference in plain language, and summarises what each is researched for in laboratory and preclinical settings. The aim is to help readers choose the right tool for their study question while keeping terminology consistent and methods sections easy to reproduce.
Core identity and sequence science
What each peptide is CJC-1295
is widely used as shorthand for a modified version of the first 29 residues of human growth hormone releasing hormone, sometimes described as a tetrasubstituted GRF 1 to 29 analogue. In practical research use, this version is treated as the compact GHRH receptor agonist scaffold, selected when investigators want a defined class B GPCR stimulus and a clean, time bounded signalling window.
CJC-1295+DAC refers to the same modified GRF core but extended by an additional lysine residue that carries a Drug Affinity Complex functionality. The core concept is not a new receptor target, it is a new molecular behaviour layer. Instead of behaving only as a free peptide, the DAC feature is designed to enable covalent bioconjugation to endogenous albumin, which can change exposure time courses in model systems and therefore change how researchers plan sampling and interpret kinetics
Sequences and the exact structural difference
The easiest way to keep the comparison clear is to anchor it to sequence and to name the difference precisely. CJC-1295 (without DAC) is commonly described as a 29 residue modified GRF core with substitutions at multiple positions and a C terminal amide. CJC-1295+DAC keeps that 29 residue core and then adds a C terminal lysine that carries the DAC functionality.
Physicochemical profile and solution behaviour
Molecular composition and formula identifiers
For method sections and reproducibility, readers usually want to understand how the two compounds differ at the composition level. The DAC form is larger because of the added lysine and DAC functionality. In practical lab work this affects how researchers convert vial mass to molar concentration, how they set up calibration standards for LC MS confirmation, and how they compare concentration response curves fairly. A simple rule for clear comparisons is to use molar matching when the question is receptor activation, because equal mass does not imply equal moles when molecular weights differ.
Stability logic tied to the GRF core substitutions
Many readers search for what makes CJC-1295 different from a native GRF 1 to 29 fragment. The common explanation is that the analogue carries specific substitutions introduced to reduce vulnerability to particular degradation routes and improve experimental reliability in relevant matrices. This is best presented as a design rationale that supports reproducible signalling experiments, rather than as a claim about outcomes in people.
• CJC-1295: smaller molecule, straightforward molar conversion, suited to short exposure signalling studies.
• CJC-1295+DAC: larger molecule, requires molar matching for fair comparisons, introduces albumin conjugation design logic.
• Method clarity: document whether comparisons are mass matched or molar matched to keep interpretation consistent.
What CJC-1295 and CJC-1295+DAC are researched for
GHRH receptor activation and class B GPCR signalling biology
The central research use case for both compounds is GHRH receptor activation, often described as pituitary GHRH receptor signalling. In laboratory settings, CJC-1295 is used to deliver a controlled receptor stimulus and then quantify downstream signalling events across time.
• Mapping receptor activation kinetics and concentration response curves in cell systems expressing GHRH receptor. Page 2 BioPlex Peptides | Science Research Studies series
• Understanding coupling to cAMP linked pathways and downstream transcriptional programmes relevant to somatotroph models.
• Comparing analogue scaffolds to see how sequence and exposure duration change measured signalling outcomes.
Endocrine axis models and secretion dynamics in preclinical designs
CJC-1295+DAC is commonly positioned as an extended exposure research tool because the albumin conjugation design can support longer sampling windows in animal models. In a research framed explanation, the DAC version is used when investigators want to examine pulsatility, sustained receptor drive, or time extended secretion dynamics in a model without continuous dosing. CJC-1295 without DAC is often treated as a shorter window analogue tool, useful when the research goal is to compare acute signalling windows, desensitisation behaviour, or recovery dynamics between pulses. Put simply, the non DAC version supports pulse style experimental design, while the DAC version supports extended window design.
Albumin binding strategy as a study variable
A clear way to present the DAC feature is as a study variable rather than a value judgement. Instead of saying it makes the peptide better, describe what it enables in research: longer sampling windows, fewer dosing events in some protocols, and a different set of experimental considerations such as albumin availability and conjugation efficiency in the model system
• CJC-1295: used in studies focused on acute GHRH receptor signalling, pulse design assays, and short window pathway mapping.
• CJC-1295+DAC: used in studies focused on extended exposure designs, prolonged endocrine axis interrogation, and albumin conjugation enabled sampling strategies.
• Shared theme: both are selected to probe GHRH receptor driven biology in controlled experimental systems.
Conclusion
CJC-1295 andCJC-1295+DAC are best understood as two research tools built from the same modified GRF core, separated by one major design choice: whether the peptide remains a compact 29 residue analogue, or whether it gains a DAC lysine extension designed for albumin bioconjugation behaviour. For clear science communication and SEO, define terms early, highlight the sequence level difference, and explain that the DAC version changes experimental timing more than it changes target identity. Researchers typically use CJC-1295 when they want short, controllable receptor activation windows, and they use CJC-1295+DAC when they want to explore longer sampling windows and sustained model dynamics driven by the same receptor pathway logic.
CJC-1295 Research Compound, available at BioPlex Peptides for laboratory research.
CJC-1295+DAC Research Compound, available at BioPlex Peptides for laboratory research.
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.